TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8746602
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg lisinopril once a day between 7 p.m. and 11 p.m.
Study: 7047579
Drug: Group C
Normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C received placebo tablets and rinsed with folate MW twice daily for 1 min
Study: 7047579
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B received placebo MW and one 5 mg folate tablet daily
Study: 7047579
Drug: Control Group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Group A received placebo mouthwash (MW) and placebo tablets
Study: 27840301
Drug: teriparatide 20‐mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: teriparatide 20‐mcg SC daily
Study: 27840301
Drug: denosumab 60‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: denosumab 60‐mg SC every 6 months
Study: 26222356
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of pharmacotherapy and lidocaine block (Group II)
Study: 26222356
Drug: No additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional treatment (Group I)
Study: 8824685
Drug: Lacidipine-based treatment
Normalized name: LACIDIPINE
DrugBank: Lacidipine (DB09236)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacidipine-based treatment (SHELL trial)
Study: 8824685
Drug: Lacidipine-based treatment
Normalized name: LACIDIPINE
DrugBank: Lacidipine (DB09236)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacidipine-based treatment (ELSA trial)
Study: 6783420
Drug: Pancreatic polypeptide
Normalized name: PANCREATIC POLYPEPTIDE
DrugBank: Pancreatic Polypeptide (DB12822)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancreatic polypeptide infusion at 1 pmol kg‐1 min‐1
Study: 6783420
Drug: Pancreatic polypeptide
Normalized name: PANCREATIC POLYPEPTIDE
DrugBank: Pancreatic Polypeptide (DB12822)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancreatic polypeptide infusion at 4 pmol kg‐1 min‐1
Study: 6783420
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no pancreatic polypeptide infusion)
Study: 6783420
Drug: Pancreatic polypeptide
Normalized name: PANCREATIC POLYPEPTIDE
DrugBank: Pancreatic Polypeptide (DB12822)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancreatic polypeptide infusion
Study: 31200985
Drug: Project Planned
Normalized name: Plan B One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Project Planned Outreach, Intervention, Naloxone, and Treatment (POINT)
Study: 23784600
Drug: Prophylactic aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prophylactic aspirin use
Study: 21635618
Drug: Autologous PRP
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous PRP injections
Study: 19543672
Drug: Methylphenidate (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (0.3 mg/kg body weight twice daily)
Study: 17626054
Drug: Shock wave
Normalized name: ELECTRODE GEL,H-WAVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shock wave therapy (SWT)
Study: 12677620
Drug: Intrathecal bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal bupivacaine 2.5 mg and fentanyl 25 microgram with epinephrine 100 microgram (Group BFE)
Study: 12677620
Drug: Control group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group: Intrathecal bupivacaine 2.5 mg and fentanyl 25 microgram without epinephrine (Group BF)
Study: 9558774
Drug: Rifaximin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin (600 mg/day x 3/day), Amoxicillin (1 g x 2/day), Omeprazole (40 mg/day) for 2 weeks (protocol A)
Study: 9558774
Drug: Rifaximin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin (600 mg/day x 3/day), Erythromycin‐ethylsuccinate (600 mg x 3/day), Omeprazole (40 mg/day) for 2 weeks (protocol B)
Study: 1531926
Drug: Terbinafine 250
Normalized name: terbinafine 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine 250 mg/day for 3 months
Study: 31027480
Drug: Abrupt discontinuation
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abrupt discontinuation of remifentanil
Study: 30554184
Drug: Topical vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical vancomycin treatment group (257 patients)
Study: 30554184
Drug: Topical vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical vancomycin treatment group
Study: 25373012
Drug: Combination inositol
Normalized name: Inositol
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combination inositol and glucomannan
Study: 19885850
Drug: Pomegranate juice
Normalized name: pomegranate juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomegranate juice (200 mL PJ/day) for 3 days before surgery
Study: 19885850
Drug: Walnuts (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Walnuts (35 g walnuts/day) for 3 days before surgery
Study: 15564311
Drug: appropriate care
Approvals — FDA: no, EMA: no, PMDA: no
Description: appropriate care without hylan G-F 20
Study: 12618280
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplementation (3.6 g/day)
Study: 10546927
Drug: Meloxicam, 15
Normalized name: Meloxicam, 15 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meloxicam, 15 mg/day
Study: 8668411
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) rehydration treatment
Study: 8668411
Drug: Oral rehydration
Normalized name: Oral rehydration salt formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rehydration solutions (ORSs) of different sodium content
Study: 1853156
Drug: 4-gram 5-aminosalicylic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-gram 5-aminosalicylic acid retention enema (Mesasal) administered for seven consecutive nights and one additional enema on the eighth night
Study: 6882699
Drug: New tricyclic
Approvals — FDA: no, EMA: no, PMDA: no
Description: New tricyclic antidepressant
Study: 31229990
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg daily for 24 months
Study: 31229990
Drug: Famotidine 40
Normalized name: famotidine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 40 mg daily for 24 months
Study: 27792396
Drug: DHA (1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA (1,500 mg/day of DHA-enriched oil)
Study: 27792396
Drug: Placebo (1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1,500 mg/day of sunflower oil)
Study: 22853818
Drug: Intravenous artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous artesunate (AS) 2 mg/kg
Study: 22853818
Drug: Intravenous artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous artesunate (AS) 4 mg/kg
Study: 22853818
Drug: Intravenous artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous artesunate (AS) 8 mg/kg
Study: 20159049
Drug: Lactobacillus salivarius
Normalized name: Lactobacillus Salivarius
DrugBank: Lactobacillus salivarius (DB16544)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus salivarius CECT5713 (2 x 10(8) CFU daily for 4 weeks)
Study: 12232452
Drug: Enoxaparin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (1 mg/kg/dose, subcutaneous, twice daily)
Study: 12232452
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (adjusted dose, intravenous)
Study: 10424385
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of mercury vapour (0.6-10 microg)
Study: 10424385
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of pure air
Study: 10424385
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of mercury vapour
Study: 28880260
Drug: Open-label steroid
Normalized name: strontium chloride, 89Sr-labeled
DrugBank: Strontium chloride Sr-89 (DB09498)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label steroid therapy
Study: 22831916
Drug: 3-month physical
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-month physical activity behavior change intervention (supervised aerobic exercise of 150 weekly minutes at moderate intensity and resistance exercise 2 sessions per week)
Study: 17710587
Drug: 15 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g/day pressurized whey protein
Study: 17710587
Drug: 30 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g/day pressurized whey protein
Study: 17710587
Drug: 45 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 g/day pressurized whey protein
Study: 1326318
Drug: 1 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/m2 body surface ACTH4-9 analog before and after each cisplatin cycle
Study: 30882166
Drug: Warm solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warm solution (37 degrees)
Study: 22646082
Drug: ABA-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABA-based therapy sessions (2-3 sessions per week for 1 year)
Study: 17571741
Drug: Yogic practices
Normalized name: Practical Alchemy Purify and Protect Duo KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yogic practices (specifics on dosage and duration not available)
Study: 11953038
Drug: CMV-specific T
Normalized name: Virus Specific T-Cell
DrugBank: Virus Specific T-Cell (DB15735)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMV-specific T cell therapy
Study: 10440303
Drug: Occupational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy intervention for up to 5 months at home
Study: 7757046
Drug: Operant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operant treatment
Study: 7757046
Drug: Operant-cognitive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operant-cognitive treatment (OC)
Study: 7757046
Drug: Operant-respondent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operant-respondent treatment (OR)
Study: 2148326
Drug: desipramine‐alprazolam combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: desipramine‐alprazolam combination
Study: 25562579
Drug: Collaborative care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collaborative care intervention (cognitive-behavioral therapy and/or pharmacotherapy)
Study: 11554424
Drug: Nicardipine HCl
Normalized name: nicardipine HCl
DrugBank: Nicardipine (DB00622)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicardipine HCl oral sustained-release dosage form
Study: 2459516
Drug: Ketanserin (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (up to a dose of 10 mg)
Study: 2459516
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of phentolamine and ritanserin
Study: 30553077
Drug: Telephone-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-delivered cognitive behavioral therapy (T-CBT)
Study: 12967481
Drug: M-CSF administered
Normalized name: m-phenylenediamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: M-CSF administered group (group 1; 19 patients)
Study: 12967481
Drug: Non-M-CSF administered
Normalized name: m-phenylenediamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-M-CSF administered group (group 2; 20 patients)
Study: 12967481
Drug: M-CSF +
Normalized name: m-phenylenediamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: M-CSF + G-CSF group
Study: 1382623
Drug: Methylprednisolone 30
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone 30 mg/kg body weight 1 1/2 hours before, and four and 12 hours after operation (n = 6)
Study: 29030894
Drug: Eslicarbazepine acetate
Normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eslicarbazepine acetate (ESL) 800 mg once-daily for 12 weeks
Study: 29030894
Drug: Eslicarbazepine acetate
Normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eslicarbazepine acetate (ESL) 1200 mg once-daily for 12 weeks
Study: 11280555
Drug: Alosetron 1
Normalized name: alosetron 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alosetron 1 mg b.i.d. for 48 weeks
Study: 20924261
Drug: Ranibizumab (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab (0.3 or 0.5 mg) monthly + sham PDT
Study: 20924261
Drug: PDT +
Normalized name: Photodynamic Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDT + monthly sham injection
Study: 9144368
Drug: licensed hepatitis
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: licensed hepatitis B virus vaccine
Study: 7910155
Drug: nebivolol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: nebivolol (5 mg o.i.d.)
Study: 7910155
Drug: atenolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: atenolol (100 mg o.i.d.)
Study: 29794482
Drug: Control arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control arm with conventional regimen (TSP followed by oral prednisolone) (n = 37)
Study: 19192368
Drug: Psychological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychological treatment (patients referred by GP)
Study: 19192368
Drug: Psychological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychological treatment (patients recruited through systematic screening)
Study: 11555394
Drug: HAART combined
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAART combined with G-CSF thrice weekly for 12 weeks (n = 6)
Study: 3060987
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (4.8 g n‐3 PUFA's) for 12 weeks
Study: 3060987
Drug: Vegetable oil
Normalized name: Vegetable Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vegetable oil (4.8 g n‐6 PUFA's) for 12 weeks
Study: 25911859
Drug: 180 μg
Normalized name: immunoglobulin G, human 180 MG/ML [GamaSTAN]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 μg peginterferon alfa-2a
Study: 25911859
Drug: 360 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 360 μg peginterferon alfa-2a
Study: 21345776
Drug: Ropivacaine 0.33%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.33% delivered at 2 mL/h for 72 hours
Study: 21345776
Drug: Saline 0.9%
Normalized name: CVS Saline 0.9% Nasal Mist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline 0.9% delivered at 2 mL/h for 72 hours (Control)
Study: 21092360
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment arm in a RCT for CFS/ME
Study: 12472516
Drug: Cophenylcaine spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cophenylcaine spray
Study: 2729123
Drug: Dilevalol (200,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilevalol (200, 400, and 800 mg for 5 days)
Study: 5312317
Drug: Twice-weekly regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly regimen of high-dosage isoniazid plus streptomycin
Study: 5312317
Drug: Once-weekly chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly chemotherapy with high-dosage isoniazid plus streptomycin
Study: 5312317
Drug: Once-weekly chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly chemotherapy with high-dosage isoniazid plus streptomycin plus high-dosage pyrazinamide
Study: 5312317
Drug: Initial daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial daily phase of 4 weeks with moderate dosage of isoniazid plus streptomycin followed by once-weekly high-dosage isoniazid plus streptomycin
Study: 29399314
Drug: Low level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low level laser therapy (LLLT) in conjunction with 100 mg carbamazepine (administered at baseline and after 2 days) for 9 sessions (3 days a week).
Study: 29399314
Drug: Sham laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham laser in conjunction with 100 mg carbamazepine (administered at baseline and after 2 days) for 9 sessions (3 days a week).
Study: 28707810
Drug: 3.75-mg GnRHa
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75-mg GnRHa
Study: 28707810
Drug: 1.88-mg GnRHa
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.88-mg GnRHa
Study: 25680817
Drug: Metyrapone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metyrapone (1 g)
Study: 14526263
Drug: Mixed AA
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed AA solution infusion at low rate (2 mg/min/kg BW)
Study: 14526263
Drug: Mixed AA
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed AA solution infusion at high rate (4.5 mg/min/kg BW)
Study: 14526263
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline infusion (control)
Study: 1468827
Drug: Continuous 48-h
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous 48-h infusion of calcitonin gene-related peptide (n = 6)
Study: 1468827
Drug: Two successive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two successive 8-h infusions of calcitonin gene-related peptide (n = 5)
Study: 1468827
Drug: Continuous 48-h
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous 48-h infusion of calcitonin gene-related peptide
Study: 23053266
Drug: Combinational therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combinational therapy (vinorelbine and capecitabine)
Study: 23053266
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy (vinorelbine followed by capecitabine)
Study: 23053266
Drug: Combinational therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combinational therapy (vinorelbine and capecitabine) in patients with liver metastases
Study: 15214555
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (40 patients randomized)
Study: 3620098
Drug: Ethanol (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0 g/kg, 0.12 g/kg, 0.6 g/kg, 1.05 g/kg lean body weight)
Study: 3620098
Drug: Ethanol (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (higher doses)
Study: 30962103
Drug: EGCG (5-7
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGCG (5-7 mg/kg/day) + Cognitive Training (CT)
Study: 26820618
Drug: Everolimus (3-6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus (3-6 ng/mL) with reduced-exposure calcineurin inhibitor (CNI; cyclosporine) to weeks 7-11 after transplant, followed by increased everolimus exposure (target 6-10 ng/mL) with cyclosporine withdrawal
Study: 23896830
Drug: Xenon inhalation
Normalized name: xenon
DrugBank: Xenon (DB13453)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xenon inhalation combined with mild therapeutic hypothermia (target concentration of at least 40%) (n=16)
Study: 23896830
Drug: Xenon inhalation
Normalized name: xenon
DrugBank: Xenon (DB13453)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xenon inhalation combined with mild therapeutic hypothermia (n=16)
Study: 20795925
Drug: Student-led progressive
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Student-led progressive resistance training program (6 exercises using weight machines, performed twice a week for 10 weeks, 3 sets of 12 repetitions or until fatigue)
Study: 17703101
Drug: Skin prick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin prick test at a concentration of 1 mg/ml
Study: 17703101
Drug: Intradermal test
Normalized name: Skin Test Antigens, Multiple Intradermal Test
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal test at a concentration of 0.1 mg/ml
Study: 17703101
Drug: Skin test
Normalized name: SKIN TEST
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin test administered before chemotherapy
Study: 14727246
Drug: Concomitant chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant chemoradiotherapy with weekly carboplatin/paclitaxel and daily subcutaneous amifostine
Study: 14727246
Drug: Concomitant chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant chemoradiotherapy with weekly carboplatin/paclitaxel without daily subcutaneous amifostine
Study: 31576651
Drug: Conventional preoperative
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional preoperative preparation (Control)
Study: 23097398
Drug: Large FSH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large FSH dose (150 mg, n=18)
Study: 23097398
Drug: Medium FSH
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium FSH dose (130 mg, n=12)
Study: 23097398
Drug: Small FSH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small FSH dose (80 mg, n=7)
Study: 16618293
Drug: Propofol 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2.5 mg x kg(‐1) preceded by fentanyl 3.0 microg x kg(‐1)
Study: 16618293
Drug: Propofol 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 3.0 mg x kg(‐1) preceded by fentanyl 3.0 microg x kg(‐1)
Study: 16618293
Drug: Propofol 3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 3.5 mg x kg(‐1) preceded by fentanyl 3.0 microg x kg(‐1)
Study: 7068935
Drug: Erythromycin base
Normalized name: Erythromycin base
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin base (250 mg, four times a day for six days)
Study: 7068935
Drug: Erythromycin stearate
Normalized name: Erythromycin Stearate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin stearate (250 mg, four times a day for six days)